Actively Recruiting
Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2025-03-13
20
Participants Needed
1
Research Sites
132 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The combination of azacitidine and venetoclax is currently considered a therapeutic strategy innovative in AML through the addition of new compounds (triplet therapies), including inhibitors of the immune checkpoint inhibitors. Despite strong motivation, the clinical results of these approaches have been disappointing overall. The mechanisms leading to treatment failure of immunotherapies in AML are poorly elucidated as the effects on the AML microenvironment induced by basic azactidine and venetoclax therapy are largely unknown. In particular, the activity of the IDO1 enzyme as a potential mechanism of microenvironment resistance has been scarcely studied. The products of the IDO1-catalysed pathway activate the signalling of the AHR in mesenchymal stem cells and enhance their immunosuppressive effects, including the ability to reprogram the phenotype of M1/M2 macrophages. Furthermore, activation of the AHR by by products of the IDO1 pathway kinurenine-promotes tolerogenic dendritic cells and the generation of regulatory T cells. Based on this rationale, TALETE-2023 will aim to analyse the leukaemia immune microenvironment through multiomics (epigenomics transcriptomics, proteomics, metabolomics) and assess its contribution to the effect of the combination of azacitidine and venetoclax.
CONDITIONS
Official Title
Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subject is �3e= 18 years of age
- Subject has a new diagnosis of AML according to World Health Organization 2022 criteria
- Subject is ineligible for intensive induction chemotherapy according to investigator assessment
- Subject will undergo front-line treatment with azacitidine and venetoclax according to normal clinical practice
- Subject providing signed written informed consent according to ICH/EU/GCP and national local laws
- For healthy donors: Age �3e= 18 years
- For healthy donors: Subject providing signed written informed consent according to ICH/EU/GCP and national local laws
You will not qualify if you...
- Subject has acute promyelocytic leukemia
- Subject has known AML with central nervous system involvement
- Subject has not initiated treatment with azacitidine and venetoclax
- For healthy donors: None
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Italy, 40138
Actively Recruiting
Research Team
A
Antonio Curti, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here